Abbott To File In Thailand For Kaletra Pediatric AIDS Indication
This article was originally published in PharmAsia News
Executive Summary
In an apparent change of position, Abbott will file for approval of a pediatric formulation of its antiretroviral protease inhibitor Kaletra (lopinavir/ritonavir) tablets in Thailand, the firm announced July 27
You may also be interested in...
Industry Eyes Thai Elections For Compulsory License’s Future
Recent elections in Thailand raise questions about the future of the country's compulsory license policy, which the Pharmaceutical Research and Manufacturers of America says erodes Thailand's intellectual property system
Industry Eyes Thai Elections For Compulsory License’s Future
Recent elections in Thailand raise questions about the future of the country's compulsory license policy, which the Pharmaceutical Research and Manufacturers of America says erodes Thailand's intellectual property system
Abbott Cuts Kaletra Price In 40 Countries
Move follows spat between firm and Thailand over country’s decision to allow generic HIV therapies.